MD20210033A2 - Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 - Google Patents
Compuşi, compoziţii şi metode pentru modularea activităţii CDK9Info
- Publication number
- MD20210033A2 MD20210033A2 MDA20210033A MD20210033A MD20210033A2 MD 20210033 A2 MD20210033 A2 MD 20210033A2 MD A20210033 A MDA20210033 A MD A20210033A MD 20210033 A MD20210033 A MD 20210033A MD 20210033 A2 MD20210033 A2 MD 20210033A2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- methods
- cdk9
- compositions
- modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Invenţia se referă la compuşi, care modulează activitatea kinazei dependente de ciclină 9 (CDK9), compoziţii farmaceutice, care conţin astfel de compuşi, şi metode de utilizare a compuşilor şi/sau compoziţiilor farmaceutice pentru tratamentul, ameliorarea şi/sau prevenirea bolilor, care apar în rezultatul activităţii CDK9, de exemplu, bolilor hiperproliferative, bolilor infecţioase, induse de virus, şi bolilor cardiovasculare.Inhibitorii ai CDK9 reprezintă derivaţi de pirazolo[1,5-a]pirimidine şi sărurile lor, corespunzători formulei (I): (I).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752635P | 2018-10-30 | 2018-10-30 | |
US201962884993P | 2019-08-09 | 2019-08-09 | |
US201962910058P | 2019-10-03 | 2019-10-03 | |
PCT/US2019/058482 WO2020092314A1 (en) | 2018-10-30 | 2019-10-29 | Compounds, compositions, and methods for modulating cdk9 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MD20210033A2 true MD20210033A2 (ro) | 2021-10-31 |
Family
ID=70328627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20210033A MD20210033A2 (ro) | 2018-10-30 | 2019-10-29 | Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 |
Country Status (20)
Country | Link |
---|---|
US (3) | US11155560B2 (ro) |
EP (1) | EP3873911A4 (ro) |
JP (1) | JP7385658B2 (ro) |
KR (1) | KR20210068597A (ro) |
CN (1) | CN112996790B (ro) |
AU (1) | AU2019370200A1 (ro) |
BR (1) | BR112021008176A2 (ro) |
CA (1) | CA3118472A1 (ro) |
CO (1) | CO2021005502A2 (ro) |
CR (1) | CR20210202A (ro) |
DO (1) | DOP2021000066A (ro) |
IL (1) | IL282254A (ro) |
MA (1) | MA54092A (ro) |
MD (1) | MD20210033A2 (ro) |
MX (1) | MX2021004769A (ro) |
PE (1) | PE20212196A1 (ro) |
PH (1) | PH12021550857A1 (ro) |
SG (1) | SG11202104229WA (ro) |
WO (1) | WO2020092314A1 (ro) |
ZA (1) | ZA202102609B (ro) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019370200A1 (en) * | 2018-10-30 | 2021-06-10 | Kronos Bio, Inc. | Compounds, compositions, and methods for modulating CDK9 activity |
WO2021216828A1 (en) * | 2020-04-24 | 2021-10-28 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
WO2022098843A1 (en) * | 2020-11-05 | 2022-05-12 | Kronos Bio, Inc. | Compounds and methods for modulating cdk9 activity |
KR20240110634A (ko) * | 2021-11-24 | 2024-07-15 | 크로노스 바이오, 인코포레이티드 | (1s,3s)-n1-(5-(펜탄-3-일)피라졸로[1,5-a]피리미딘-7-일)시클로펜탄-1,3-디아민의다형체 및 염 형태 |
WO2024017365A1 (zh) * | 2022-07-22 | 2024-01-25 | 上海海雁医药科技有限公司 | 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
AU680370B2 (en) | 1994-06-21 | 1997-07-24 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo(1,5-a)pyrimidine derivative |
WO1998003510A1 (en) | 1996-07-24 | 1998-01-29 | Du Pont Pharmaceuticals Company | AZOLO TRIAZINES AND PYRIMIDINES |
US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
KR20020047198A (ko) | 1999-09-30 | 2002-06-21 | 해피 페너 ; 해리 에이치. 페너 2세 | 특정 알킬렌 디아민-치환된피라졸로[1,5-a]-1,5-피리미딘 및피라졸로[1,5-a]-1,3,5-트리아진 |
CA2379633C (en) | 1999-09-30 | 2006-06-20 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
JP2002308879A (ja) | 2001-04-13 | 2002-10-23 | Nippon Soda Co Ltd | 5−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤 |
CA2483306A1 (en) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
ES2287476T3 (es) | 2002-05-10 | 2007-12-16 | Smithkline Beecham Corporation | Pirazolopirimidinas sustituidas. |
MXPA04012245A (es) | 2002-06-04 | 2005-09-30 | Neogenesis Pharmaceuticals Inc | Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales. |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
WO2004026229A2 (en) * | 2002-09-04 | 2004-04-01 | Schering Corporation | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
NZ539165A (en) | 2002-09-04 | 2008-03-28 | Schering Corp | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
GB0305559D0 (en) | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
EP1608652A1 (en) * | 2003-03-31 | 2005-12-28 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
US20070060595A1 (en) | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
EP1697369A1 (en) | 2003-12-22 | 2006-09-06 | SB Pharmco Puerto Rico Inc | Crf receptor antagonists and methods relating thereto |
US8018479B2 (en) | 2008-08-27 | 2011-09-13 | Lexmark International, Inc. | Method and system for correcting the linearity error in electrophotographic devices |
AU2005272298A1 (en) * | 2004-08-13 | 2006-02-16 | Teijin Pharma Limited | Pyrazolo[1,5-a]pyrimidine derivative |
JP2008524330A (ja) | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | ピラゾロ[1,5−A]ピリミジンアデノシンA2a受容体アンタゴニスト |
DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
US8188097B2 (en) | 2005-10-21 | 2012-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-A]pyrimidine compounds |
US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
BRPI0712016A2 (pt) | 2006-05-22 | 2011-12-27 | Schering Corp | pirazolo[1,5-a]pirimidinas |
JP2010529140A (ja) * | 2007-06-05 | 2010-08-26 | エモリー・ユニバーシテイ | サイクリン依存性キナーゼの選択的阻害剤 |
EP2173346A2 (en) | 2007-06-27 | 2010-04-14 | Summit Corporation Plc | Use of compounds for preparing anti-tuberculosis agents |
CN102143746A (zh) * | 2008-07-03 | 2011-08-03 | 埃克塞利希斯股份有限公司 | Cdk 调节剂 |
JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
US8575177B2 (en) | 2009-12-04 | 2013-11-05 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
KR101478889B1 (ko) | 2010-02-26 | 2015-01-02 | 미쓰비시 타나베 파마 코퍼레이션 | 피라졸로피리미딘 화합물 및 pde10 억제제로서의 그의 용도 |
WO2011108689A1 (ja) | 2010-03-05 | 2011-09-09 | 協和発酵キリン株式会社 | ピラゾロピリミジン誘導体 |
PE20130395A1 (es) | 2010-06-24 | 2013-04-10 | Gilead Sciences Inc | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral |
JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
US8957077B2 (en) | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
CN104066736B (zh) | 2012-01-10 | 2017-03-08 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的吡唑并嘧啶 |
SG10201606581RA (en) | 2012-02-17 | 2016-09-29 | Millennium Pharm Inc | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme |
WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
CA2889919C (en) | 2012-11-16 | 2021-08-17 | University Health Network | Pyrazolopyrimidine compounds |
EP2970309A4 (en) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
GB201403093D0 (en) * | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP3125907A4 (en) | 2014-04-01 | 2017-11-29 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
EP3129371B1 (en) | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN107530329B (zh) | 2015-03-09 | 2021-10-08 | 奥瑞基尼探索技术有限公司 | 用作CDK抑制剂的吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物 |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2016169995A1 (en) | 2015-04-20 | 2016-10-27 | AbbVie Deutschland GmbH & Co. KG | Substituted pyrazolopyrimidines and method of use |
CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
EP3356330B1 (en) | 2015-10-01 | 2019-11-20 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
US11112410B2 (en) | 2016-04-13 | 2021-09-07 | President And Fellows Of Harvard College | Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof |
US20190060296A1 (en) * | 2017-07-28 | 2019-02-28 | Massachusetts Institute Of Technology | Discovery of small molecules that target the androgen receptor and uses |
BR112020001714A2 (pt) | 2017-07-28 | 2020-07-21 | Nimbus Lakshmi, Inc. | inibidores de tyk2 e usos dos mesmos |
AU2019370200A1 (en) * | 2018-10-30 | 2021-06-10 | Kronos Bio, Inc. | Compounds, compositions, and methods for modulating CDK9 activity |
-
2019
- 2019-10-29 AU AU2019370200A patent/AU2019370200A1/en active Pending
- 2019-10-29 CN CN201980072853.7A patent/CN112996790B/zh active Active
- 2019-10-29 SG SG11202104229WA patent/SG11202104229WA/en unknown
- 2019-10-29 BR BR112021008176-3A patent/BR112021008176A2/pt unknown
- 2019-10-29 EP EP19878830.9A patent/EP3873911A4/en active Pending
- 2019-10-29 MD MDA20210033A patent/MD20210033A2/ro unknown
- 2019-10-29 PE PE2021000604A patent/PE20212196A1/es unknown
- 2019-10-29 US US16/667,027 patent/US11155560B2/en active Active
- 2019-10-29 MA MA054092A patent/MA54092A/fr unknown
- 2019-10-29 WO PCT/US2019/058482 patent/WO2020092314A1/en active Application Filing
- 2019-10-29 JP JP2021521232A patent/JP7385658B2/ja active Active
- 2019-10-29 CA CA3118472A patent/CA3118472A1/en active Pending
- 2019-10-29 KR KR1020217016498A patent/KR20210068597A/ko unknown
- 2019-10-29 CR CR20210202A patent/CR20210202A/es unknown
- 2019-10-29 MX MX2021004769A patent/MX2021004769A/es unknown
-
2021
- 2021-04-12 IL IL282254A patent/IL282254A/en unknown
- 2021-04-14 DO DO2021000066A patent/DOP2021000066A/es unknown
- 2021-04-15 PH PH12021550857A patent/PH12021550857A1/en unknown
- 2021-04-20 ZA ZA2021/02609A patent/ZA202102609B/en unknown
- 2021-04-27 CO CONC2021/0005502A patent/CO2021005502A2/es unknown
- 2021-09-15 US US17/476,237 patent/US11845754B2/en active Active
-
2023
- 2023-11-03 US US18/386,964 patent/US20240132506A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11155560B2 (en) | 2021-10-26 |
US20220002305A1 (en) | 2022-01-06 |
US20240132506A1 (en) | 2024-04-25 |
WO2020092314A1 (en) | 2020-05-07 |
CR20210202A (es) | 2022-02-08 |
DOP2021000066A (es) | 2021-10-31 |
IL282254A (en) | 2021-05-31 |
PE20212196A1 (es) | 2021-11-16 |
EP3873911A4 (en) | 2022-06-22 |
PH12021550857A1 (en) | 2021-12-06 |
SG11202104229WA (en) | 2021-05-28 |
JP2022505268A (ja) | 2022-01-14 |
CN112996790A (zh) | 2021-06-18 |
CA3118472A1 (en) | 2020-05-07 |
KR20210068597A (ko) | 2021-06-09 |
AU2019370200A1 (en) | 2021-06-10 |
MA54092A (fr) | 2021-09-08 |
BR112021008176A2 (pt) | 2021-08-03 |
CN112996790B (zh) | 2023-11-03 |
CO2021005502A2 (es) | 2021-09-20 |
US11845754B2 (en) | 2023-12-19 |
US20200131189A1 (en) | 2020-04-30 |
ZA202102609B (en) | 2023-02-22 |
EP3873911A1 (en) | 2021-09-08 |
MX2021004769A (es) | 2021-08-24 |
JP7385658B2 (ja) | 2023-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD20210033A2 (ro) | Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 | |
MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
MX2020014245A (es) | Inhibidores de quinasas dependientes de ciclinas. | |
PH12019501941A1 (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
CA2962914C (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
EA201991884A3 (ru) | Ингибиторы g12c kras | |
MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
WO2017204445A3 (ko) | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
EA202091372A1 (ru) | Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2 | |
PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
WO2015200677A3 (en) | Prmt5 inhibitors and uses thereof | |
MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
MY193511A (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
MX2021014455A (es) | Inhibidores de proteina cinasas dependientes de adn. | |
EA201691930A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1 | |
WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
PH12017501699A1 (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
MX2023011065A (es) | Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1. | |
MY201291A (en) | Aminothiazole compounds as protein kinase inhibitors | |
MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
PH12017501334B1 (en) | 3,5-diaminopyrazole kinase inhibitors | |
EA201990046A1 (ru) | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета | |
MX2021000917A (es) | Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe. |